Get started
Author

Anita Mazloom

Observed name: ANITA MAZLOOM
ORCID: 0009-0009-7899-7078
Observed ORCID: 0009-0009-7899-7078
OpenAlex ID: A5087952943
Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals
2025 · Jordan Snyder, Shebli Atrash, et al. · Cancers · 6
PDF
Cemiplimab in advanced cutaneous squamous cell carcinoma: A real-world experience of outcomes and safety.
2022 · Sunil Badami, Anita Mazloom, et al. · Journal of Clinical Oncology · 4
Extramedullary Pulmonary Manifestations of Relapsed/Refractory Multiple Myeloma: A Case Series and Brief Review of the Literature
2024 · Sagar Kumar, Anita Mazloom, et al. · Journal of Respiration · 2
PDF
High-Risk Cytogenetic Multiple Myeloma Remains a Therapeutic Challenge: A 15-Year Real-World Analysis
2026 · Carmel Awadallah, Anas Zayad, et al. · Current Oncology · 1
PDF
Investigation of cardiotoxicity with concomitant use of anthracyclines and checkpoint inhibitors.
2024 · Anita Mazloom, Jose Alejandro Asturias, et al. · Journal of Clinical Oncology · 1
Impact of bone marrow involvement in patients with peripheral T-cell lymphoma undergoing autologous stem cell transplant.
2022 · Robert Stuver, Anita Mazloom, et al. · Journal of Clinical Oncology · 1
Extramedullary Disease and Prolonged Hematotoxicity After Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A Transatlantic Real-World Evidence Synthesis
2026 · Mohammad Ahsen Soomro, Aroog Khaliq, et al. · Current Oncology
Sequencing BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma: A Real-World Comparison of CAR T-Cell Therapy and Bispecific Antibodies
2026 · Osama M. Younis, Sencer Goklemez, et al. · Cancers
POSTER: MM-846: Treatment-Related Mortality and Predictors in Real-World Patients With Relapsed/Refractory Multiple Myeloma Treated With Teclistamab
2026 · Osama Younis, Sencer Goklemez, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-846: Treatment-Related Mortality and Predictors in Real-World Patients With Relapsed/Refractory Multiple Myeloma Treated With Teclistamab
2026 · Osama Younis, Sencer Goklemez, et al. · Clinical Lymphoma Myeloma & Leukemia
Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRC
2026 · Nagham Youssef, Maha Hameed, et al. · Current Oncology
PDF
From episodic assessment to comprehensive assessment: integrating real-world monitoring in relapsed/refractory multiple myeloma
2026 · Carmel Awadallah, Shebli Atrash, et al. · Expert Review of Hematology
Maintenance Strategies in High-Risk Myeloma: A Multicenter Comparison of Bortezomib–Lenalidomide Versus Lenalidomide Alone: A USMIRC Multicenter Analysis
2026 · Sruthi P. Ramanan, Oyepeju F. Abioye, et al. · Current Oncology
PDF
Clinical outcomes and barriers of autologous hematopoietic stem cell transplantation in newly diagnosed high-risk multiple myeloma in a non-transplant center: Assessing the impact of transplant accessibility on racial minorities
2025 · Abraham Titus, Hussein Haidari, et al. · Blood
Sequential Paraneoplastic Endocrine Syndromes in Small Cell Lung Cancer
2024 · MUHAMMAD AREEB ASHFAQ, ANITA MAZLOOM, et al. · CHEST Journal
Identifying Primary Refractory Disease and Early Relapses in Peripheral T-Cell Lymphoma Using Baseline Characteristics, Minimal Residual Disease, and Mutational Profiling
2022 · Robert Stuver, Harleigh Haynie, et al. · Blood
Works count: 16
Citation count: 15
H-index: 2
I10-index:
Year
Topic
Type